Business Wire

MI-EATON

2.12.2021 12:32:10 CET | Business Wire | Press release

Share
Eaton Introduces Variable Valve Actuation Technologies to Help Commercial Truck Makers Meet Upcoming China Emissions Regulations

Power management company Eaton today announced its Vehicle Group has introduced a complete portfolio of variable valve actuation (VVA) technologies to help commercial vehicle manufacturers meet forthcoming emissions regulations in China. The regulations are expected to be significantly more stringent than current standards.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005043/en/

“Automakers that manufacture vehicles for the China market are researching how to achieve future emissions regulations,” said Fabiano Contarin, product director, Commercial Vehicle Valvetrain, Eaton’s Vehicle Group. “Eaton is the right partner to support this effort because of our considerable experience helping European and U.S. auto and truck makers develop emissions-reducing technologies."

Eaton’s VVA solutions are based on two building blocks: 1) a rocker with a switchable capsule, and 2) a split rocker for full deactivation. By combining these two building blocks, several VVA strategies can be utilized in virtually any engine architecture – single and dual overhead cam, as well as cam-in-block engines – and engine displacement ranging from 2.0 liters to 15.0 liters.

Vehicle Group’s CDA technology lowers CO2 and NOx simultaneously

Cylinder deactivation (CDA) is a VVA technology that involves deactivating the intake and exhaust valve opening, as well as the fuel injection on some cylinders when an engine is running at low load. This increases the temperature of the exhaust gases, allowing the nitrogen oxide (NOx) aftertreatment to remain efficient at low load and decrease carbon dioxide (CO2 ) emissions.

CDA is an ideal solution for commercial vehicles that make frequent stops, such as sanitation or delivery trucks. It decreases both NOx and CO2 simultaneously, making it more efficient than other technologies that cut NOx at the expense of increased CO2 . CDA can reduce NOx by more than 40% and CO2 by 5%-8%.

Late intake valve closing technology reduces emissions

Eaton also offers Late Intake Valve Closing (LIVC), which delays the closing of the intake valve, so the effective compression ratio is lower than the expansion ratio. LIVC increases the thermal efficiency of the engine, improving fuel economy and reducing CO2 emissions. Reducing the amount of airflow through the engine with a shorter intake stroke raises the exhaust temperature by 40 degrees Celsius, contributing to the thermal management of the aftertreatment. Overall, LIVC can reduce CO2 by 1%-2%, and is most efficient for applications such as over-the-road trucks.

Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kinaxis-Sponsored Study Identifies Supply Chain AI Accountability Gap Amidst Rapid Adoption Expectations11.8.2026 14:07:00 CEST | Press release

Trust, measurable outcomes, and governance lag, even as 41% expect autonomous-at-scale operations within two years Kinaxis® (TSX:KXS), a global leader in supply chain orchestration, today announced the findings of new independent research from IDC. The IDC InfoBrief, sponsored by Kinaxis, “Making Supply Chain AI Accountable,” reveals a growing chasm between organizations’ aggressive ambitions for autonomous AI adoption and their readiness to hold these advanced systems - which we believe underscores the need for a disciplined approach to AI investment and deployment to prevent costly failures and deliver measurable business value. What This Means for Supply Chain Leaders The IDC InfoBrief, which surveyed more than 2,000 supply chain leaders across nine global markets, found that while AI adoption is nearly universal - only 2% of respondents report no AI-enabled capabilities, and just 12% consider themselves AI leaders. Over half (52%) cite trust in AI-driven decisions as a top barrier

One in Four Executives Say AI Errors Have Reached External Audiences or Boards, According to New Research From Workiva11.8.2026 14:00:00 CEST | Press release

Although 84% of executives are at least somewhat confident in AI output without human review, only 11% believe their data quality is sufficient for AI use Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today released findings from its 2026 Midyear Executive Benchmark Survey. Although 84% of surveyed executives say they are at least somewhat confident in the accuracy of AI output without human review, one in four (26%) say internal audits have detected AI errors that reached external audiences or board members. This data suggests there is a disconnect between what executives believe and what evidence shows. As AI reshapes the enterprise at unprecedented speed, a new risk is emerging: transformation could be outpacing the instincts of the leaders tasked with overseeing it. "Confidence in AI without control over data quality is a liability, not a strategy. CFOs need platforms that connect AI to trusted, auditable data so every output

Altasciences Continues to Expand North American Bioanalytical Footprint11.8.2026 14:00:00 CEST | Press release

Altasciences today announced a major expansion of its North American bioanalytical laboratory footprint, reinforcing its commitment to helping sponsors accelerate drug development through increased capacity, advanced automation, and harmonized scientific operations. The expansion includes a 4,000-square-foot addition to the company’s laboratory in Greater Montréal, which is expected to be fully operational by the end of Q3 2026. The company has also announced a new 13,000-square-foot purpose-built laboratory in Harleysville, Pennsylvania. Construction will proceed in phases, with Phase 1 scheduled for completion in Q1 2027. These investments significantly increase Altasciences' ability to support the growing demand for late-stage clinical bioanalysis while providing sponsors with greater flexibility, scalability, and operational resilience. Designed to support increasingly complex development programs, the expanded laboratories will result in increased capacity to conduct larger studie

Alfasigma to Acquire Nordic Group B.V. Expanding Its Specialty Care Portfolio and Presence in Europe11.8.2026 13:30:00 CEST | Press release

Transaction highlights Advances Alfasigma’s M&A-led global growth strategy, purposely focused on immunology and gastroenterology. Synergy with Alfasigma’s specialty rheumatology portfolio, adding Nordic Pharma’s rheumatoid arthritis business, including the Nordimet® franchise. Expands footprint by adding Canada and Japan; strengthens presence in Europe, with direct operations in 18 countries, with 265 employees. Adds approximately €190 million in 2025 revenue. Financial terms of the transaction are not disclosed. Alfasigma S.p.A. (“Alfasigma”), a global pharmaceutical company, today announced that it has entered into a share purchase agreement with SEVER Life Sciences B.V. ("SEVER") for the sale of 100% of the shares of Nordic Group B.V. (“Nordic Pharma”) and its subsidiaries, a privately owned specialty pharmaceutical company with direct operations in Europe, Canada and Japan. The acquisition will add Nordic Pharma’s established rheumatoid arthritis business, led by the Nordimet® meth

Organigram Reports Record Third Quarter Fiscal 2026 Results11.8.2026 12:00:00 CEST | Press release

Record Quarterly Revenue and Adjusted EBITDA(1) Driven by Acquisition of Sanity Group Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the “Company” or “Organigram”), Canada's #1 cannabis company by market share2 and a growing global cannabis platform following its acquisition of Sanity Group GmbH (“Sanity” or “Sanity Group”), today announced its results for the third quarter ended June 30, 2026 (“Q3 Fiscal 2026” or “Q3”). Q3 FISCAL 2026 HIGHLIGHTSGross Revenue: $145.1 million (+32% year-over-year). Net Revenue: $105.8 million (+49% year-over-year). Adjusted EBITDA1: $13.4 million (+136% year-over-year). #1 Market Share in Canada: #1 in vapes, #1 in milled flower, #1 in concentrates, #2 in flower, #2 in pre-rolls, #3 in edibles, and #4 in beverages2. Sanity Group: Since the acquisition closed on April 15, 2026, Sanity has performed in line with management's expectations, contributing approximately €25 million (C$40 million) in net revenue to Organigram's consolidated results. During t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye